Phase III CONCERT trial of latrepirdine: Negative results

Pharmaceutical Medicine

Volumn 26, Issue 2, 2012, Pages 113-115

  Sweetlove, Mel ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Drug utilisation; Endpoints; Pharmaceutical industry; Pharmacoepidemiology; Randomised controlled trials

Indexed keywords

DIMEBON; DONEPEZIL; PLACEBO;

ADJUVANT THERAPY; ADULT; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ALZHEIMER DISEASE COOPERATIVE STUDY ACTIVITIES OF DAILY LIVING INVENTORY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 84858642778     PISSN: 11782595     EISSN: 11791993     Source Type: Journal    
DOI: 10.2165/11631260-000000000-00000     Document Type: Article

References (11)

1. Medivation Inc. Medivation and Pfizer announce results fromphase 3CONCERT trial of Dimebon in Alzheimer's disease [media release]. 2012 Jan 17 [online]. Available from URL: http://www.medivation.com [Accessed 2012 Feb 21]
2. Pfizer Inc., Medivation Inc. Pfizer and Medivation announce results from two phase 3 studies in Dimebon (latrepirdine) Alzheimer's disease clinical development program [media release]. 2010 Mar 4 [online]. Available from URL: http://www.pfizer.com [Accessed 2012 Feb 22]
3. Bachurin S, Bukatina E, Lermontova N, et al. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci 2001; 939: 425-35 (Pubitemid 32620096)
4. Lermontova NN, Lukoyanov NV, Serkova TP, et al. Dimebon improves learning in animals with experimental Alzheimer's disease. Bull Exp Biol Med 2000; 129 (6): 544-6
5. Grigor'ev VV, Garibova TL, Voronina TA, et al. Effects of the chronic administration of dimebon on behaviour and memory of SAMP 10 mice [in Russian]. Eksp Klin Farmakol 2009; 72 (1): 52-6
6. Giorgetti M, Bernales S, Alfaro IE, et al. Cognition enhancement by Dimebon (latrepirdine) is not mediated by acetylcholinesterase inhibition or NMDA receptor modulation [abstract no. 155 plus poster]. 48th Annual Meeting of the American College of Neuropsychopharmacology; 2009 Dec 6-10; Hollywood (FL
7. Hung D. Dimebon: a phase 3 investigational agent for Alzheimer's disease with a novel mitochondrial mechanism of action [abstract S4-04-05]. 12th InternationalConference onAlzheimer's Disease andRelatedDisorders; 2008 Jul 26-31; Chicago (IL
8. Bachurin SO, Shevtsova EP, Kireeva EG, et al. Mitochondria as a target for neurotoxins and neuroprotective agents. AnnNYAcad Sci 2003; 993: 334-44; discussion 345-9
9. Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mildto- moderate Alzheimer's disease: a randomised, double-blind, placebocontrolled study. Lancet 2008; 372 (9634): 207-15 (Pubitemid 351978110)
10. Sabbagh MN, Berk C. Latrepirdine for Alzheimer's disease: trials and tribulations. Future Neurology 2010; 5 (5): 645-51
11. Jones RW. Dimebon disappointment [commentary]. Alzheimers Res Ther 2010; 2 (5): 25